|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
HUP0104607A3
(en)
*
|
1998-12-15 |
2002-12-28 |
Warner Lambert Co |
Use of a mek inhibitor for preventing transplant rejection
|
|
EP1140067A1
(en)
*
|
1999-01-07 |
2001-10-10 |
Warner-Lambert Company |
Antiviral method using mek inhibitors
|
|
AP2001002225A0
(en)
|
1999-01-13 |
2001-09-30 |
Warner Lambert Co |
1-heterocycle substituted diarylamines.
|
|
IL144214A0
(en)
|
1999-01-13 |
2002-05-23 |
Warner Lambert Co |
Benzoheterocycles and their use as mek inhibitors
|
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
|
ATE311363T1
(de)
|
1999-01-13 |
2005-12-15 |
Warner Lambert Co |
Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
|
|
EP1144371B1
(en)
|
1999-01-13 |
2005-11-09 |
Warner-Lambert Company Llc |
Benzenesulphonamide derivatives and their use as mek inhibitors
|
|
US6686499B1
(en)
|
1999-04-21 |
2004-02-03 |
Warner-Lambert Company |
Method for making 2-(N-phenylamino)benzoic acids
|
|
PL351085A1
(en)
*
|
1999-04-21 |
2003-03-24 |
Warner Lambert Co |
Method for making 2-(n-phenylamino)benzoic acids
|
|
GB9910577D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
AU5786000A
(en)
*
|
1999-07-16 |
2001-02-05 |
Warner-Lambert Company |
Method for treating chronic pain using mek inhibitors
|
|
BR0109188A
(pt)
*
|
2000-03-15 |
2003-03-18 |
Warner Lambert Co |
Diarilaminas 5-amida substituìdas como inibidores de mex
|
|
US7001905B2
(en)
|
2000-03-15 |
2006-02-21 |
Warner-Lambert Company |
Substituted diarylamines as MEK inhibitors
|
|
DE10017480A1
(de)
*
|
2000-04-07 |
2001-10-11 |
Transmit Technologietransfer |
Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
|
|
IL153817A0
(en)
*
|
2000-07-19 |
2003-07-31 |
Warner Lambert Co |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
MXPA03001654A
(es)
*
|
2000-08-25 |
2004-09-10 |
Warner Lambert Co |
Proceso para la elaboracion del acido n-aril-antranilico y sus derivados.
|
|
US20020054869A1
(en)
|
2000-09-01 |
2002-05-09 |
Han-Mo Koo |
Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
|
|
AU2002210714A1
(en)
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
|
US7253184B2
(en)
|
2000-11-02 |
2007-08-07 |
Astrazeneca Ab |
4-Substituted quinolines as antitumor agents
|
|
AU2002255852B2
(en)
*
|
2001-03-22 |
2006-11-09 |
Van Andel Research Institute |
Anthrax lethal factor inhibits tumor growth and angiogenesis
|
|
IL149462A0
(en)
*
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
|
EP1467968A1
(en)
|
2002-01-23 |
2004-10-20 |
Warner-Lambert Company LLC |
N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
|
|
DOP2003000556A
(es)
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
CA2478374C
(en)
|
2002-03-13 |
2009-01-06 |
Eli M. Wallace |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
WO2005009975A2
(en)
|
2003-07-24 |
2005-02-03 |
Warner-Lambert Company Llc |
Benzimidazole derivatives as mek inhibitors
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
WO2005028426A1
(ja)
|
2003-09-19 |
2005-03-31 |
Chugai Seiyaku Kabushiki Kaisha |
新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
|
|
CN100594212C
(zh)
|
2003-10-21 |
2010-03-17 |
沃纳-兰伯特公司 |
N-[(r)-2,3-二羟基-丙氧基]-3,4-二氟-2-(2-氟-4-碘苯基氨基)-苯甲酰胺的多晶型物
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
JP4869075B2
(ja)
|
2003-11-19 |
2012-02-01 |
アレイ バイオファーマ、インコーポレイテッド |
Ｍｅｋの複素環阻害剤及びその使用方法
|
|
BRPI0416852A
(pt)
|
2003-11-21 |
2007-02-27 |
Array Biopharma Inc |
inibidores da quinase akt
|
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
|
JP2007530654A
(ja)
*
|
2004-03-30 |
2007-11-01 |
ファイザー・プロダクツ・インク |
シグナル伝達阻害剤の組合せ
|
|
MY144232A
(en)
|
2004-07-26 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
|
KR100889721B1
(ko)
|
2004-08-17 |
2009-03-23 |
에프. 호프만-라 로슈 아게 |
치환 히단토인
|
|
TW200621766A
(en)
*
|
2004-09-17 |
2006-07-01 |
Hoffmann La Roche |
Substituted hydantoins
|
|
AR051248A1
(es)
|
2004-10-20 |
2007-01-03 |
Applied Research Systems |
Derivados de 3-arilamino piridina
|
|
US8022247B2
(en)
|
2005-04-06 |
2011-09-20 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of 2,3,4-trifluoro-5-(iodo or bromo)-benzoic acid
|
|
RU2500673C2
(ru)
|
2005-05-18 |
2013-12-10 |
Астразенека Аб |
Гетероциклические ингибиторы мек и способы их применения
|
|
EP1934174B1
(en)
|
2005-10-07 |
2011-04-06 |
Exelixis, Inc. |
Azetidines as mek inhibitors for the treatment of proliferative diseases
|
|
US7612212B2
(en)
|
2006-02-22 |
2009-11-03 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
EP2025347A4
(en)
|
2006-05-15 |
2010-08-11 |
Takeda Pharmaceutical |
PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
WO2008006039A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
|
WO2008006025A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
PL2049500T3
(pl)
|
2006-07-06 |
2012-02-29 |
Array Biopharma Inc |
Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
|
|
EP1908751A1
(en)
*
|
2006-10-03 |
2008-04-09 |
EOS S.p.A. |
N-hydroxy benzamides with antitumour activity
|
|
KR20090071666A
(ko)
|
2006-10-23 |
2009-07-01 |
다케다 야쿠힌 고교 가부시키가이샤 |
Ｍａｐｋ／ｅｒｋ 키나아제 억제제
|
|
JP5311673B2
(ja)
|
2006-12-14 |
2013-10-09 |
エグゼリクシス， インコーポレイテッド |
Ｍｅｋ阻害剤の使用方法
|
|
JPWO2008075741A1
(ja)
*
|
2006-12-20 |
2010-04-15 |
国立大学法人 長崎大学 |
糖尿病治療剤及び予防剤
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
EP2404907B1
(en)
|
2007-07-05 |
2015-01-14 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
BRPI0813999A2
(pt)
|
2007-07-05 |
2019-10-01 |
Array Biopharma Inc |
ciclopentanos de pirimidil como inibidores de akt proteína cinase
|
|
JP2010536723A
(ja)
|
2007-08-16 |
2010-12-02 |
エフ．ホフマン−ラ ロシュ アーゲー |
置換ヒダントイン
|
|
WO2009080523A1
(en)
|
2007-12-20 |
2009-07-02 |
F. Hoffmann-La Roche Ag |
Substituted hydantoins as mek kinase inhibitors
|
|
AU2009204019B2
(en)
|
2008-01-09 |
2014-02-20 |
Array Biopharma Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
|
KR101624753B1
(ko)
|
2008-01-09 |
2016-05-26 |
어레이 바이오파마 인크. |
Ａｋｔ 단백질 키나제 저해물질로서의 수산화된 피리미딜 시클로펜탄
|
|
US8530457B2
(en)
|
2008-05-20 |
2013-09-10 |
Fox Chase Cancer Center |
Method for the treatment of lymphangioleiomyomatosis (LAM)
|
|
DK2307376T3
(en)
|
2008-08-04 |
2016-01-11 |
Merck Patent Gmbh |
NOVEL phenylamino ISONIKOTINAMIDFORBINDELSER
|
|
PA8840701A1
(es)
|
2008-08-27 |
2010-04-21 |
Leo Pharma As |
NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS
|
|
WO2010051933A2
(en)
|
2008-11-10 |
2010-05-14 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted sulphonamido phenoxybenzamides
|
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
US8962606B2
(en)
|
2009-10-21 |
2015-02-24 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
CA2777071A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
CA2777430A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011106298A1
(en)
|
2010-02-25 |
2011-09-01 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
AU2011224410B2
(en)
|
2010-03-09 |
2015-05-28 |
Dana-Farber Cancer Institute, Inc. |
Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
|
|
US9045429B2
(en)
|
2010-10-29 |
2015-06-02 |
Bayer Intellectual Property Gmbh |
Substituted phenoxypyridines
|
|
CN106893692B
(zh)
|
2010-12-22 |
2021-11-26 |
菲特治疗公司 |
用于单细胞分选与增强ipsc重新编程的细胞培养平台
|
|
BR112013025397A2
(pt)
|
2011-04-01 |
2019-09-24 |
Deepak Sampath |
combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
|
|
CA2831922C
(en)
|
2011-04-01 |
2019-12-31 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and vemurafenib, and methods of use
|
|
ES2597052T3
(es)
|
2011-05-25 |
2017-01-13 |
Université Paris Descartes |
Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
|
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
HRP20180670T1
(hr)
|
2012-10-12 |
2018-07-13 |
Exelixis Inc. |
Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
|
|
WO2015038704A1
(en)
|
2013-09-11 |
2015-03-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
EP3094736A4
(en)
|
2014-01-14 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
|
SG10201807292YA
(en)
|
2014-03-04 |
2018-09-27 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
AU2016338680B2
(en)
|
2015-10-16 |
2022-11-17 |
Fate Therapeutics, Inc. |
Platform for the induction and maintenance of ground state pluripotency
|
|
CN108473961B
(zh)
|
2015-11-04 |
2022-11-29 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
KR20250141836A
(ko)
|
2015-11-04 |
2025-09-29 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
|
CA3010236A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
WO2017127755A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
JP7194436B2
(ja)
*
|
2016-07-28 |
2022-12-22 |
ザ ジョンズ ホプキンス ユニバーシティ |
Ｏ－置換ヒドロキサム酸
|
|
JP7098615B2
(ja)
|
2016-12-05 |
2022-07-11 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
CN107556201B
(zh)
*
|
2017-09-08 |
2020-10-27 |
山西智创药研科技有限公司 |
一种制备间氨基苯酚的工艺方法
|
|
WO2020106305A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
JP7576799B2
(ja)
*
|
2018-11-20 |
2024-11-01 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
|
|
AU2020242287A1
(en)
|
2019-03-21 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|